Sign up to save your podcasts
Or
Share Setting glycaemic targets: a patient-centred approach | With Prof. Peter Rossing
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Setting glycaemic targets: a patient-centred approach | With Prof. Peter Rossing
As part of the patient-centred care model described by the ADA & EASD in their 2018 consensus report, glycaemic targets should be individualised and set collaboratively with the patient. But how should we approach these consultations, and what happens if the target is not met? Join us for a discussion of this topic with Professor Peter Rossing, Head of Complications Research at Steno Diabetes Center Copenhagen, Professor of Endocrinology at the University of Copenhagen and an author of the ADA/EASD consensus report on the management of hyperglycaemia in type 2 diabetes.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
References:
Disclosures:
Professor Rossing reports advisor fees (fee to institution) and research grants from AstraZeneca and Novo Nordisk, advisor fees (fee to institution) from Astellas, Bayer, Gilead, Vifor, Boehringer Ingelheim, Eli Lilly and Sanofi.
Funding statement:
This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
View all episodes
By Liberum IME
5
11 ratings
As part of the patient-centred care model described by the ADA & EASD in their 2018 consensus report, glycaemic targets should be individualised and set collaboratively with the patient. But how should we approach these consultations, and what happens if the target is not met? Join us for a discussion of this topic with Professor Peter Rossing, Head of Complications Research at Steno Diabetes Center Copenhagen, Professor of Endocrinology at the University of Copenhagen and an author of the ADA/EASD consensus report on the management of hyperglycaemia in type 2 diabetes.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
References:
Disclosures:
Professor Rossing reports advisor fees (fee to institution) and research grants from AstraZeneca and Novo Nordisk, advisor fees (fee to institution) from Astellas, Bayer, Gilead, Vifor, Boehringer Ingelheim, Eli Lilly and Sanofi.
Funding statement:
This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp & Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.